Physician profile
Michelly R De Castro
NPI 1841687308
$6,948.43
in general payments reported to CMS, 2019-2025
14 companies · $3,340 in 2025
The $3,340 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,193 · 2022: $1,889 · 2023: $48.75 · 2024: $477 · 2025: $3,340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,330 · Food and Beverage: $957 · Travel and Lodging: $397 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,330.00 |
| Food and Beverage | $956.91 |
| Travel and Lodging | $397.30 |
| Education | $182.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,848.18 | 2021-2025 | Darzalex, Carvykti, Tecvayli |
| Kite Pharma, INC. | $905.54 | 2021-2025 | Yescarta |
| Glaxosmithkline, LLC. | $645.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $358.38 | 2024-2025 | Talvey, Tecvayli, Carvykti |
| Pfizer INC. | $355.34 | 2024-2025 | |
| Seagen INC. | $221.47 | 2022 | |
| Celgene Corporation | $197.73 | 2021-2025 | Breyanzi |
| E.R. Squibb & Sons, L.L.C. | $121.97 | 2022 | |
| Legend Biotech USA INC. | $112.67 | 2022-2025 | Carvykti |
| Amgen INC. | $65.00 | 2021 | |
| Daiichi Sankyo INC. | $52.48 | 2021 | |
| Jazz Pharmaceuticals INC. | $30.97 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $21.32 | 2021 | |
| Karyopharm Therapeutics INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelly De Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.